Abstract Details

Title Effectiveness and Safety of ABAStroke in Cognitive Rehabilitation for Post-stroke Patients: A Randomized Controlled Study

Topic Neuro-rehabilitation

Presentation(s) P7 - Poster Session 7 (5:00 PM-6:00 PM)

Poster/Presentation
Number 4-003

Objective

To assess the effectiveness and safety of ABAStroke in cognitive rehabilitation for post-stroke patients, as measured by the Montreal Cognitive Assessment (MoCA), compared to standard therapy.

Background

ABAStroke is an AI-based mobile app designed for home rehabilitation of cognitive deficits in post-stroke patients. The app uses Applied Behavior Analysis (ABA) principles to target attention, memory, executive functions, visuospatial perception, and thinking.

Design/Methods This randomized controlled trial included 76 adult patients (18–75 years) who had experienced ischemic or hemorrhagic stroke within the last 6 months and had MoCA scores between 14 and 26. The study group (n=38) used ABAStroke in addition to standard therapy, while the control group (n=38) received only standard care. Patients were followed for up to 104 days. Statistical tests, including Kolmogorov-Smirnov and Mann-Whitney, were used to assess outcomes. Outliers were identified and excluded.

Results

A total of 74 patients completed the study. Four patients from the study group did not complete the required ABAStroke sessions and were excluded from the analysis. After outlier removal, 32 patients in the study group and 34 in the control group were analyzed. The study group showed significant improvement in MoCA scores compared to the control group (mean difference: 1.6875, p=0.001276). No serious adverse events were reported.

Conclusions ABAStroke demonstrated over 84% effectiveness in cognitive rehabilitation, surpassing traditional methods (60-80% reported in the literature). These results suggest that ABAStroke is an effective digital therapeutic tool with the potential to complement or replace traditional rehabilitation approaches. Further studies should explore long-term effects and cost-effectiveness.

Authors/Disclosures
Pawel Wrona, MD PRESENTER	Dr. Wrona has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZeneca. Dr. Wrona has received research support from ABAStroke Company.
Bartlomiej M. Piechowski-Jozwiak, MD (Cleveland Clinic Abu Dhabi)	Dr. Piechowski-Jozwiak has nothing to disclose.
Tomasz Homa, MD	Mr. Homa has received research support from ABAStroke Company.
Ewa Wlodarczyk, MD	Dr. Wlodarczyk has nothing to disclose.
Paulina E. Sarba, MD	Miss Sarba has received research support from ABAStroke Company.
Agnieszka Slowik, MD, FAAN (Jagiellonian University)	Dr. Slowik has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Boehringer, . Dr. Slowik has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Slowik has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis.

��ɫ��

��ɫ��